Leading the charge in cervical disease prevention with the ThinPrep^® system and Aptima^® HPV assays

Hologic has remained an unwavering advocate for women’s health for more than two decades. Our goals as a company are intrinsically tied to changes in best-practices for women’s health, applying the latest findings in diagnostic medicine to the development of new products and technologies in response to the emergence of new discoveries in medicine.

Women’s health testing streamlined with just one swab. With innovative nucleic acid amplification test (NAAT) technology and a single collection device, the Aptima Multitest Swab simplifies testing and provides more answers for sexual and vaginal health.

FDA-Approved solution to reliably and efficiently deliver actionable viral load insights to post-transplant patients and their care teams.  

Deliver trusted results with dual targets across a wide linear range and all major HBV genotypes.

Confirmation of active HCV infection and monitoring HCV viral load on the fully automated Panther® system.  

Globally, over 4.1 billion people are infected with HSV-1 and HSV-2 and the signs and symptoms can overlap.¹ It is only through laboratory tests that these subtypes can be differentiated, which is important for managing herpes infections and identifying the risk of transmission to neonates and among sex partners.^2,3

 

STI testing for improved sexual health. The Aptima STI portfolio supports sexual health testing with a comprehensive, flexible menu of sexually transmitted infection (STI) assays.

Trichomonas vaginalis (TV) is the most common curable STI in the United states.1 Over 3.7 million people in the United States have TV, which is a higher prevalence than chlamydia and gonorrhea infections combined.1 The CDC recommends testing women for TV infection if they are symptomatic or at increased risk of infection.2 The CDC and ACOG also recommend the use of a highly sensitive and specific test, such as the Aptima® Trichomonas vaginalis assay.2,3

The Aptima vaginitis panel from Hologic consists of molecular nucleic acid amplification tests (NAAT) to aid in the detection of vaginosis and vaginitis. Our assays detect the three most common causes of infectious vaginitis: bacterial vaginosis, candida vaginitis and trichomoniasis.

The Aptima Virology portfolio delivers on the Hologic promise of innovation through life-changing viral testing for viruses that impact patients across the globe.

Transform specimen processing with the only nasopharyngeal (NP) swab that loads directly for COVID testing.

Transform Specimen Processing for COVID Testing

The emergence of SARS-CoV-2 was unforeseen, and the worldwide outbreak of COVID-19 has already impacted millions Since then, the need and recommendations for testing for SARS-CoV-2 have continuously evolved, requiring labs to be flexible with their strategies over time. Hologic’s SARS-CoV-2 portfolio and scalable automation enable labs to react to these changing needs and fully automate COVID-19 testing. With Panther® Scalable Solutions, you can run over 1000 tests in 24 hours, attaining first results in about 3 hours.^1† The Panther Fusion® SARS-CoV-2 assay is a real-time PCR test and the Aptima® SARS-CoV-2 assay utilizes our proprietary TMA® technology. Both assays are intended for the qualitative detection of RNA from SARS-CoV-2 isolated and purified from nasopharyngeal, nasal, mid-turbinate and oropharyngeal swab specimens, nasopharyngeal wash/aspirate or nasal wash, and lower respiratory tract specimens (Panther Fusion assay only) obtained from individuals who meet COVID-19 clinical and/or epidemiological criteria.^2,3 These assays are also intended for upper respiratory tract swab samples from individuals without symptoms or other reasons to suspect COVID-19 infection. The Aptima SARS-CoV-2/Flu assay utilizes our proprietary real-time TMA chemistry to detect and differentiate SARS-CoV-2, influenza A and influenza B from nasopharyngeal and nasal swabs obtained from individuals with signs and symptoms of a respiratory tract infection or who meet COVID-19 clinical and/or epidemiological criteria.⁴

Give patients a better chance at life with our Transplant Portfolio of quantitative tests for the quantification of post-transplant infections.  

CMV and Viral Load Monitoring